LUCD

Lucid Diagnostics Inc.

• TipRanks·10/01 16:20

  Needham sees no reason for Lucid Diagnostics selloff today

• TipRanks·09/23 17:55

  Analyst Reiterates Buy on Lucid Diagnostics as Medicare, Coding Tailwinds Support EsoGuard; $2 Price Target Maintained

• TipRanks·09/22 13:29

  Lucid Diagnostics advances Medicare reimbursement and coding infrastructure

• Dow Jones·08/27 11:52

  Lucid Diagnostics Is Maintained at Buy by Ascendiant Capital

• TipRanks·08/27 11:45

  Lucid Diagnostics price target raised to $9.50 from $9.25 at Ascendiant

• TipRanks·08/22 00:27

  Lucid Diagnostics Earnings Call Balances Progress and Risk

• TipRanks·08/17 11:37

  Analyst Reaffirms Buy on Lucid Diagnostics, Sees Upside to $2.50 Target on Coverage Momentum and Validated EsoGuard Utility

• Dow Jones·08/17 10:09

  Lucid Diagnostics Price Target Maintained With a $2.50/Share by BTIG

• TipRanks·08/17 07:54

  Lucid Diagnostics reports Q2 non-GAAP EPS (6c), consensus (5c)

• TipRanks·08/14 12:56

  Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group

• Dow Jones·08/14 12:00

  Press Release: PAVmed Provides Business Update -2-

• TipRanks·08/13 15:30

  Analysts’ Top Healthcare Picks: Lucid Diagnostics (LUCD), Takeda Pharmaceutical Company (TAK)

• NASDAQ·08/13 13:10

  Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates

• TipRanks·08/13 12:48

  Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision

• Seeking Alpha·08/13 12:13

  Lucid Diagnostics Non-GAAP EPS of -$0.06 misses by $0.01, revenue of $1.47M misses by $0.46M